Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C53F | ISIN: US92332V1070 | Ticker-Symbol:
NASDAQ
17.04.24
21:59 Uhr
4,385 US-Dollar
0,000
0,00 %
1-Jahres-Chart
VENTYX BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
VENTYX BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur VENTYX BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.04.Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares2
05.04.Ventyx Biosciences, Inc. - 8-K, Current Report2
12.03.Ventyx rebounds as Oppenheimer upgrades after pipeline updates2
12.03.SIGA, VTYX and SGLY are among pre market gainers3
12.03.Oppenheimer upgrades Ventyx stock, sets $12 target on 'Pipeline Prospects'3
11.03.Ventyx stock tumbles 18% amid pipeline updates2
11.03.What's Going On With Autoimmune/Inflammatory Disorder-Focused Ventyx Biosciences On Monday?2
11.03.Lexicon Pharmaceuticals, Mesoblast, Ventyx Biosciences among healthcare movers4
11.03.Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event199VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2...
► Artikel lesen
07.03.Ventyx Biosciences, Inc. - 8-K, Current Report3
07.03.Ventyx Biosciences, Inc.: Ventyx Biosciences Announces $100 Million Private Placement of Common Stock3
28.02.Ventyx Biosciences GAAP EPS of -$0.792
27.02.Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress189Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash...
► Artikel lesen
21.02.Weight-Loss Drug Hype Sends Biotech Ventyx's Stock Soaring on Rival's Data10
21.02.Ventyx surges as Piper highlights potential against obesity7
06.02.Ventyx Biosciences, Inc.: Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference3
02.01.Ventyx Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
08.12.23Ventyx lays off 20% of staff after cutting TYK2 indications, seeing share price plummet6
08.12.23Ventyx Biosciences cuts 20% of workforce 1
07.12.23Ventyx Biosciences, Inc. - 8-K, Current Report2
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1